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Abstract
hMena and the epithelial specific isoform hMena11a are actin cytoskeleton regulatory proteins belonging to the Ena/VASP
family. EGF treatment of breast cancer cell lines upregulates hMena/hMena11a expression and phosphorylates hMena11a,
suggesting cross-talk between the ErbB receptor family and hMena/hMena11a in breast cancer. The aim of this study was to
determine whether the hMena/hMena11a overexpression cooperates with HER-2 signalling, thereby affecting the HER2
mitogenic activity in breast cancer. In a cohort of breast cancer tissue samples a significant correlation among hMena, HER2
overexpression, the proliferation index (high Ki67), and phosphorylated MAPK and AKT was found and among the molecular
subtypes the highest frequency of hMena overexpressing tumors was found in the HER2 subtype. From a clinical viewpoint,
concomitant overexpression of HER2 and hMena identifies a subgroup of breast cancer patients showing the worst
prognosis, indicating that hMena overexpression adds prognostic information to HER2 overexpressing tumors. To identify a
functional link between HER2 and hMena, we show here that HER2 transfection in MCF7 cells increased hMena/hMena11a
expression and hMena11a phosphorylation. On the other hand, hMena/hMena11a knock-down reduced HER3, AKT and p44/
42 MAPK phosphorylation and inhibited the EGF and NRG1-dependent HER2 phosphorylation and cell proliferation. Of
functional significance, hMena/hMena11a knock-down reduced the mitogenic activity of EGF and NRG1. Collectively these
data provide new insights into the relevance of hMena and hMena11a as downstream effectors of the ErbB receptor family
which may represent a novel prognostic indicator in breast cancer progression, helping to stratify patients.
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Introduction
Breast cancer is a heterogeneous disease and in recent years the
introduction of new targeted therapeutic approaches highlights the
need to stratify patients and consequently to identify accurate
biomarkers to select the best therapeutic choice. The molecular
classification of breast tumors has identified tumor subtypes,
among which the overexpression of the ErbB family of receptors is
confined to tumors with unfavourable prognosis [1]. The human
ErbB receptor family comprises four tyrosine kinases members
(EGFR, HER2, HER3 and HER4) and their deregulation has
been correlated with cancer development and progression [1,2].
Upon ligand binding ErbB receptors undergo homodimerization
or heterodimerization and activate a complex signalling network
that controls tumor cell proliferation as well as motility through
different pathways that regulate rearrangements of the actin
cytoskeleton [3]. HER2 functions as a common co-receptor
recruited from EGFR or HER3 upon binding to their ligands [4]
and HER2/HER3 heterodimer has been defined as the major
oncogenic unit in HER2 positive breast cancer [5,6]. The two
main signalling pathways downstream from the ErbB receptors are
the phosphatidylinositol 39-kinase (PI3K) and the mitogen
activated protein kinase (MAPK) [4]. PI3K activation results in
the phosphorylation of PIP2 to yield PIP3 which in turn activates
several downstream signalling molecules including AKT and
regulates actin regulatory proteins such as cofillin and capping
proteins [7,8]. MAPK activation is responsible for the EGF
dependent mitogenic effect in normal and transformed mammary
epithelia [9] and its role in cell cycle progression is also sustained
by cytoskeletal organization [10].
hMena (ENAH), the human ortholog of murine Mena [11], is a
member of the Ena/VASP protein family which in mammalians
includes Mena, VASP and Evl. Ena/VASP are key actin
regulatory molecules that control cell shape, adhesion and
migration [12,13], processes that are frequently deregulated
following neoplastic transformation. Ena/VASP proteins behave
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as homo and heterotetramers, and the functions of the three
members are redundant in cells and in vivo. However, only Mena
may be regulated by the tumor suppressor Tes, which binds the
EVH1 domain of Mena and not VASP or EVL through an
unconventional Lim-domain mediated interaction [14].
Recently, we have demonstrated that hMena overexpression
represents an early marker of breast tumorigenesis, being
undetectable in normal breast epithelium, and overexpressed in
benign breast lesions with an increased risk of transformation and,
in more than 70% of tumors, with HER2+, ER/PgR- and high
Ki67 phenotype [15]. While Neuregulin-1 (NRG1) and EGF
growth factors induce an increase of hMena expression, Herceptin
treatment down-regulates hMena in breast cancer cell lines
overexpressing HER2 [15,16]. The hMena isoform hMena11a,
recently characterized by our group, shows an additional 21 amino
acids betweeen the F-actin binding and the coiled-coild domain in
the EVH2 domain which possesses three putative phosphorylation
sites [16]. This isoform undergoes phosphorylation upon long term
stimulation with EGF, associated with p44/42 MAPK activation
and with an increased proliferation rate in breast cancer cell lines
[16]. hMena11a expression is associated with an epithelial
phenotype [16,17,18] and identifies human pancreatic adenocar-
cinoma cell lines that are sensitive to the EGFR inhibitor Erlotinib
[17]. Thus, we hypothesize that cross-talk takes place between the
ErbB receptor family and hMena.
In the present work, through a combination of experimental
and in vivo studies, we have demonstrated that hMena/hMena11a
are downstream targets of HER2 activity and that they affect
HER2 signalling. Moreover, hMena overexpression is a frequent
event in the HER2 breast tumor subtype and significantly
correlates with HER2 overexpressing tumors and an activated
status of MAPK and AKT. On the contrary, depletion of hMena
by specific RNA interference reduces the phosphorylation of
HER3, p44/42 MAPK and AKT and inhibits both EGF and
NRG1-mediated phosphorylation of HER2 and EGFR as well as
cell proliferation. Of note in breast cancer patients, undetectable
levels of hMena are more frequent in luminal breast tumors, and
discriminate HER2 overexpressing tumors with downstream
inactive pathways carried by patients that have a better prognosis.
Conversely, the concomitant overexpression of HER2 and hMena
identifies a subgroup of breast cancer patients with a worse
prognosis indicating that hMena overexpression adds prognostic
information in HER2 overexpressing tumors.
Results
hMena overexpression occurs more frequently in the
HER2 subtype and correlates with Ki67, MAPK and AKT
activity
We have evaluated hMena expression in a series of 286 primary
breast cancer (BC) classified in Luminal A (ERa/PR+ HER2-),
Luminal B (ERa/PR+ HER2+), Triple Negative (ERa/PR/
HER22) and HER2 subtype (ERa/PR2 HER2+), as indicated in
Table 1. The immunohistochemical analysis demonstrated a
significant linear trend (p= 0.022) between hMena and HER2
expression, independent of breast tumor subtype. Figure 1 panel A
shows the frequency of HER2 positive tumors (2+ with gene
amplification and 3+ score) with different hMena staining. Of
interest, hMena is differently distributed within the four BC
subtypes (p = 0.032). In fact, only 29% of the Luminal A and
Luminal B subtypes overexpressed hMena with a score 3, whereas
48% and 44% of the HER2 and the Triple Negative subtypes,
respectively showed hMena overexpression (Figure 1 panel B).
To analyze downstream signalling pathways of the ErbB family
by immunohistochemistry (IHC), the expression of the phospho-
MAPK (P-MAPK) and phospho-AKT (P-AKT) were analyzed in
178 BC randomly selected from the entire series of 286 patients
included in our study. The IHC findings, reported in Figure 1
panel C, clearly demonstrate a significant correlation between
hMena (score 3), HER2 overexpression (p= 0.021) and the
proliferation index as assessed by Ki-67 (p,0.0001), as we have
already reported in a different cohort of patients [15]. A strong
correlation among hMena overexpression and P-AKT and P-
MAPK positivity (p,0.0001 in both cases) was found. Immuno-
histochemical analyses of serial sections of a representative invasive
BC are reported in Figure 1 panel D.
Table 1. Clinico-pathological characteristics of the patients.
CHARACTERISTICS No of cases %
Number of patients 286
Median age, y (range) 53 (28–86)
hMena
Negative (score 0/1) 96 34
Positive (score 2/3) 190 66
Histotype
Invasive ductal carcinoma 246 86
Invasive lobular carcinoma 28 10
Other carcinomas 12 4
Histologic grade
Grade 1 27 10
Grade 2 146 54
Grade 3 96 36
Lymph node status
Negative 154 54
Positive 132 46
Tumor size
T1 171 60
T2 80 29
T3,4 28 11
ER
Negative 89 31
Positive 197 69
PgR
Negative 107 37
Positive 179 63
Ki67
Negative (#15) 164 57
Positive (.15) 122 43
HER-2
Negative 204 71
Positive 82 29
Molecular Subtypes
Luminal A 177 62
Luminal B 34 12
Triple Negative 27 9
HER2 subtype 48 17
doi:10.1371/journal.pone.0015852.t001
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To evaluate the role of hMena overexpression in MAPK and
AKT activation, we categorized in hMena negative (score 0/1)
and hMena positive (score 2/3) 60 HER2 positive and 118 HER2
negative primary BC of 178 cases analyzed. As reported in Figure 2
panel A, only 17% and 11% HER2-positive/hMena-negative
tumors expressed P-MAPK and P-AKT, whereas the majority of
HER2-positive/hMena-positive tumors showed an activated status
of both MAPK (83.1%) and AKT (89%). In HER2 negative
tumors hMena expression has a minor contribution in MAPK and
AKT activity, suggesting that hMena overexpression cooperates
with HER2 in sustaining MAPK and AKT activity. Interestingly,
as shown in a representative, although not paradigmatic case
Figure 1. hMena is differently distributed among breast cancer subtypes and correlates with HER2 overexpression, MAPK, AKT
activity and Ki67. A. Relationship between hMena staining and HER2 positivity in human breast carcinomas. Histograms represent the percentage
of the hMena staining (score 0; 1; 2; 3) in 82 HER2 positive breast cancer samples (2+ with gene amplification and 3+) (p = 0.02). B. hMena distribution
within 286 human breast carcinomas grouped according to molecular subtypes. hMena expression (0, 1, 2, 3 scores) in Luminal A, Luminal B, HER2
subtypes and Triple Negative. The percentage of hMena-positive cases (score 3) is significantly higher in the HER2 subtype and Triple-Negative in
comparison to Luminal A and Luminal B breast cancer (p = 0.032). C. Correlation between hMena expression and HER2, P-AKT, P-MAPK and Ki67 in a
subgroup of 178 breast cancer patients. Percentage of HER2 positivity, high Ki67 proliferation index, elevated P-AKT and P-MAPK expression for each
hMena score. The percentage of HER2 positivity (p = 0.016), P-AKT (p,0.001) and P-MAPK (p,0.001) overexpression, high Ki67 proliferation index
(p = 0.016) increase significantly in relationship to hMena score (0 to 1 to 2 to 3). D. Representative case of an invasive ductal carcinoma with a strong
hMena positivity (score 3+) displaying HER2 overexpression (score 3 by IHC), P-MAPK and P-AKT positivity, elevated Ki67 index. Magnification, 40x.
Original scale 1 cm=30micron (25 cm633 cm).
doi:10.1371/journal.pone.0015852.g001
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(Figure 2 panel B) in which P-MAPK displayed a heterogeneous
immunostaining (40% tumor cells), hMena positivity was mainly
found in the tumor area positive for P-MAPK and viceversa.
HER2 overexpression and activity affect hMena/hMena11a
overexpression in human breast cancer cell lines
We previously reported that epithelial cancer cell lines express
hMena and the epithelial specific hMena11a isoform [16]. To
investigate the functional link between hMena/hMena11a and
HER2, we stably transfected HER2 in MCF7, a luminal epithelial
breast cancer cell line with low HER2 endogenous levels [19].
HER2 overexpression in MCF7 cells leads to the upregulation of
hMena and hMena11a compared to control cells (MCF7-
pCDNA3) as evaluated by pan-hMena and specific hMena11a
antibodies (Figure 3 panel A). This was associated with a
phosphorylation of the tyrosine Y1248 in HER2 receptor and
the activation of MAPK and PI3K as documented by the amount
of phosphorylated p44/42 MAPK and AKT (Figure 3 panel A).
Phosphorylation at Y1248 of HER2 was also observed in BT474
and SKBr3 BC cells, naturally overexpressing HER2 and hMena/
hMena11a (Figure 3 panel B). Real-time qRT-PCR experiments
demonstrated a 4 fold upregulation of hMena mRNA in MCF7-
HER2 cells with respect to MCF7-pcDNA3 control cells.
Treatment for 24 h of MCF7-pcDNA3 and SKBr3 cells
respectively with NRG1 (10 ng/ml) and EGF (100 ng/ml), factors
that indirectly activate HER2 by heterodimerization with HER3
and EGFR respectively, determined an increase in hMena RNA
(1.8 and 2.1 fold respectively) (Figure 3 panel C). These results
show that the growth factor-mediated hMena protein upregulation
reported previously [15,16] is related to an increase in hMena
mRNA and indicate that HER2 overexpression and activity
contribute to hMena/hMena11a overexpression in BC cell lines.
HER2 overexpression affects hMena11a phosphorylation
in breast cancer cells
EGF treatment of BC cell lines promotes concomitant up-
regulation of hMena and hMena11a, resulting in a higher fraction
of phosphorylated hMena11a isoform. Moreover, hMena11a
overexpression and phosphorylation lead to an increase in p44/
42 mitogen-activated protein kinase (MAPK) activation and cell
proliferation [16]. Thus we analyzed whether hMena11a phos-
phorylation is downstream to HER2 signalling. T47D and MCF7
cells, with low endogenous levels of HER2 [19], display only
modest hMena11a phosphorylation as evaluated by 2D-E analysis
(Figure 4, panels A and B). Conversely, SKBr3 cells, endogenously
overexpressing highly phosphorylated HER2 (Figure 3 panel B)
Figure 2. hMena overexpression correlates with the phosphorylated status of MAPK and AKT. A. The table evidences that in 60 HER2
positive and 118 HER2 negative breast tumors the percentage of P-MAPK and P-AKT positive breast tumors is significantly higher in hMena positive
(score 2/3) than in hMena negative breast tumors (score 0/1). B. A representative, although not a paradigmatic case, where P-MAPK displays a
heterogeneous immunostaining (40% tumor cells). P-MAPK positivity is mostly confined in the tumor area (positive area) concomitantly showing a
strong hMena (score 3) immunoreactivity.
doi:10.1371/journal.pone.0015852.g002
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show high amounts of phosphorylated hMena11a (Figure 4 panel
A). To better define hMena11a as a downstream target of HER2,
the levels of hMena11a phosphorylation were evaluated in MCF7-
HER2 cells. As depicted by the pattern of spots presented in
Figure 4 panel B, a higher percentage (77.7% vs. 63.7%) of
phosphorylated hMena11a was seen in the MCF7-HER2 with
respect to control (MCF7) cells, as revealed by the more
pronounced shift toward lower pH, which is significantly reduced
by l phosphatase treatment. Herceptin treatment down-regulates
hMena in MCF7-HER2 cells (data not shown), confirming our
previous results in endogenously HER2 overexpressing BC cell
lines [15]. Thus, to determine if Herceptin treatment is able to
inhibit HER2-dependent hMena11a phosphorylation, MCF7-
HER2 cells were treated with Herceptin 25 mg/ml for 48 h, and
the percentage of phosphorylated hMena11a was reduced (58.7%
vs 77.7%) to a level similar to that observed after l phosphatase
treatment (Figure 4 panel B).
To evaluate whether hMena11a phosphorylation is further
increased by ligand dependent HER2 activation, we treated
MCF7-HER2 cells either with EGF or NRG1. After 24 h of EGF
treatment, a higher amount of hMena11a was phosphorylated
(80.2%) compared to untreated starved cells (68.3%) (Figure 4
panel C), suggesting that paracrine signals may affect hMena11a
phosphorylation. NRG1 treatment induced a phosphorylation
pattern of hMena11a (80.8%), similar to that observed with EGF
treatment. Overall, these results show that hMena11a is down-
stream to either the EGFR/HER2 or HER2/HER3 signal
transduction pathways. These findings were confirmed in the
spontaneously HER2 overexpressing SKBr3 cells where treatment
with both EGF and NRG1 slightly increased the phosphorylation
level of the constitutively high phosphorylated hMena11a (data not
shown).
hMena knock-down inhibits ErbB family signalling and
the EGF/NRG1-mediated mitogenic effect in MCF7-HER2
cells
To investigate whether hMena/hMena11a overexpression could
affect HER2 expression and activation, the MCF7-HER2 cells
were depleted for hMena/hMena11a by siRNA. hMena silencing
in starved cells did not affect HER2 and EGFR expression and
phosphorylation, but was associated with a reduction in phospho-
HER3, phospho-AKT and phospho-p44/42 MAPK levels
(Figure 5 panel A). On the other hand, hMena/hMena11a
knock-down prevented EGF and NRG1 mediated HER2 and
EGFR activation. In particular, hMena/hMena11a depleted cells
(si-hMena) treated with EGF or NRG1 for 24 h showed a
reduction of phospho-HER2 and phospho-EGFR levels with
respect to control cells (Si-CNTR) (Figure 5 panel A). Phospho-
HER3 was not detectable following EGF and NRG1 treatment,
due to treatment induced down-regulation of the HER3 protein,
more evident in the hMena/hMena11a depleted cells.
To explore the hypothesis that hMena/hMena11a might have a
functional role in EGF and NRG1 mediated mitogenic effects, 3H-
thymidine incorporation assays were performed. hMena/hMe-
na11a knock-down induced a slight decrease in the proliferation
rate of the silenced MCF7-HER2 cells with respect to the control
in untreated conditions and abolished the proliferation activity
mediated by EGF and NRG1 (Figure 5 panel B). Similar results
were obtained in MDA-MB-361 cells naturally expressing high
levels of HER2 and HER3 (Figure 5 panel C and Figure S1). On
Figure 3. HER2 overexpression and activity affect hMena/hMena11a expression in human breast cancer cell lines. A. HER2 transfection
affects hMena expression in MCF7 breast cancer cells. Western blot analysis of MCF7-pcDNA3 and MCF7-HER2 lysates (50 mg) with the indicated
antibodies. Two different antibodies for hMena have been used: the pan-hMena antibody, recognizing hMena and hMena11a as a doublet of 88–
90 kDa, and the anti-hMena11a specific antibody. Membranes were sequentially stripped and reprobed with the indicated total and phospho-specific
antibodies. B. hMena/hMena11a expression in HER2 overexpressing breast cancer cell lines. Western blot analysis of BT474 and SKBr3 breast cancer
cell line lysates (50 mg) with the indicated antibodies. As loading control, blots were probed with anti-Actin mAb (1 mg/ml). C. HER2 transfection, NRG
and EGF treatment affect hMena expression at mRNA level. QRT-PCR analysis of hMena and housekeeping b-Actin mRNA levels performed on 10 ng
of total RNA from the untreated MCF7-pcDNA3, HER2 transfected MCF7, or NRG1 treated MCF7 breast cancer cell line and SKBr3 cells either untreated
or treated with EGF. Results are given as the ratio between hMena and b-Actin genes relative to the internal control.
doi:10.1371/journal.pone.0015852.g003
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the contrary, in MCF7, cells with a low HER2 level, hMena/
hMena11a knock-down (Figure S1) has no significant effect on the
proliferation rate in untreated conditions or in EGF treated cells.
A slight effect was observed in NRG1-mediated proliferation
(Figure 5 panel B).
hMena overexpression adds prognostic information in
BC patients with HER2 overexpressing tumors
In view of the biochemical and functional data obtained, the
prognostic impact of hMena overexpression on disease free
survival (DFS) was further estimated in our series of 286 BC
patients with a median follow-up of 45 months (1–188 months) in
which 88 relapses were recorded.
When the whole series was analyzed by unadjusted Kaplan-
Meier curves, hMena/HER2 covariates had different effect on DFS
(Figure 6). In particular, in HER2 negative cases hMena positivity
slightly reduced the DFS (78.7% BC patients bearing HER2-/
hMena- primary tumor and 71.3% with HER2-/hMena+ tumors
were disease free after 6 years follow up). Differently, among the
HER2 positive cases, only 20.6% of the patients were disease free at
a 6 year of follow-up when hMena was overexpressed with respect
to 39.3% of patients with HER2+/hMena- tumors (p,0.0001).
Figure 4. HER2 overexpression affects hMena11a phosphorylation in breast cancer cells. A. Proteins from T47D and SKBr3 cell lines were
resolved by 2D-electrophoresis on a pH 3–10 nonlinear range and 7.5% acrylamide SDS-PAGE. Proteins were then electrontransferred to
nitrocellulose and hMena reactivity was revealed by Western blot. Protein spot trains were compared by using Progenesis PG240 v2006 software
(Nonlinear dynamics, Newcastle, UK). The set of spots corresponding to hMena and hMena11a are indicated including the isoelectric point range
(dashed line). The phosphorylation threshold (arrows and vertical bars) has been arbitrarily defined as described [13]. B. Lysates of MCF7 cells, either
stably transfected with HER2 or with empty vector (pcDNA3) were resolved by 2D-electrophoresis as described above, showing that a higher fraction
of hMena11a is constitutively phosphorylated in MCF7-HER2 cells. MCF7-HER2 cells treated with Herceptin for 48 h (MCF7-HER2+ HRC) show a fraction
of phosphorylated hMena11a similar to the dephosphorylated MCF7-HER2 lysates. MCF7-HER2 cell lysates were also incubated without or with l-
phosphatase (l-PPase) before 2D analysis. Arrows indicated hMena11a spots after phosphatase treatment. Below the densitometric analysis of the
hMena spots revealed by Western blot in MCF7-HER2 cells treated without (- HRC) or with Herceptin for 48 h (+ HRC) are shown. Arrows indicated
hMena11a spots that, after Herceptin treatment, resulted to be dephosphorylated. Pseudo-colours three-dimensional view has been obtained by
using Progenesis PG240 v2006 software. C. Proteins from the MCF7-HER2 cell lines incubated with or without 100 ng/ml EGF or 10 ng/ml NRG1 for
24 h in serum starved medium, were resolved by 2D-electrophoresis and analyzed as described in panel A.
doi:10.1371/journal.pone.0015852.g004
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These data indicate that hMena overexpression adds prognostic
information in breast cancer patients with HER2 overexpressing
tumors.
Discussion
Previous experimental and in vivo data from our group suggested
that the cytoskeleton regulatory protein hMena and its splice-
variant deriving isoform, hMena11a, may couple ErbB family
signalling to the actin cytoskeleton leading to cell proliferation in
breast cancer [16]. HER2 positive breast cancers vary greatly in
prognosis and response to therapy, underlying the need to identify
newmarkers to further stratify HER2 positive tumors [20]. Here we
present our attempts to provide clinical and experimental evidence
that hMena/hMena11a are downstream targets and effectors of
HER2 activity. The clinical data show that a link exists between
hMena and HER2 overexpression, confirming our previous results
[15,16] and further evidences that, according to the molecular
classification of breast tumors [21], hMena overexpression is more
frequent in the HER2 subtype. On the other hand, the finding that
hMena overexpression is correlated with the expression of
phosphorylated MAPK and AKT and a high proliferation index
in a cohort of primary breast tumors suggests a role for hMena in
sustaining an activated status of HER2 pathways. Thus we
attempted to delineate the mechanisms linking HER2 activity with
hMena in breast cancer cell lines. Exogeneous overexpression of
Figure 5. hMena knock-down affects HER2 signalling and inhibits the EGF/NRG1-mediated mitogenic effects in MCF7-HER2 cells. A.
Western blot analysis of MCF7-HER2 breast cancer cell line after 72 h transfection with control and hMena/hMena11a -specific siRNAs, untreated or
treated with EGF (100 ng/ml) or NRG1 (10 ng/ml) for the last 24 h of transfection. hMena/hMena11a expression (evaluated by pan-hMena and
hMena11a specific antibodies) and phosphorylation status of HER2, EGFR, HER3, AKT and MAPK (p44/42) from whole cell lysates were assessed.
Membranes were sequentially stripped and reprobed with the indicated total and phospho-specific antibodies. Densitometric quantitation of anti-P-
HER2, anti-P-AKT and anti-P-MAPK immunoreactivity was determined by Quantity One software (Biorad) and normalized in comparison with the Actin
immunoreactivity. Densitometric quantitation of anti-P-HER3 immunoreactivity was not determined due to the fact that the total HER3 expression
level is not unchanged following treatments. B–C. Silencing of hMena/hMena11a reduces EGF and NRG1-mediated cell proliferation of HER2
overexpressing MCF7-HER2 (B) and MDA-MB-361 (C) cell lines, but has no significant effect in MCF7 cells (B). Proliferation assays were conducted 72 h
after the siRNA transfection by measuring [3H]thymidine incorporation as described in Materials and Methods. Si-CNTR: MCF7, MCF7-HER2 and MDA-
MB-361 cells transfected with non-targeting siRNA; Si-hMena: MCF7, MCF7-HER2 and MDA-MB-361 cells transfected with specific hMena/hMena11a
siRNA. Histograms represent the mean of three different experiments. Bars, Standard deviations. P, according to Student’s t test (two tailed).
doi:10.1371/journal.pone.0015852.g005
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HER2 or stimulation by EGF and NRG1 of different breast cancer
cell lines induce the up-regulation of hMena both at the mRNA and
protein levels, which suggests a link between ErbB family activation
and hMena. Apart from the hMena overexpression, HER2
activation promotes the phosphorylation of the epithelial specific
hMena11a isoform [16]. This is indicated by the higher percentage
of phosphorylated hMena11a observed in the MCF7-HER2 cells
with respect to control and confirmed by the hMena11a dephos-
phorylation in the same cells treated with Herceptin. Although
further studies are needed to clarify the role of hMena11a
phosphorylation, we hypothesize it may alter the regulation of
actin dynamics, since the 11a peptide is located in the EVH2
domain, the site of protein tetramerization and binding to the grown
ends of actin filaments. Studies are in progress in order to define the
residue and the kinase involved in phosphorylation. A recent work
has described Evl-I, a splice variant derived isoform of Evl, that
similarly to hMena11a shows a 21aa peptide included in the EVH2
domain which is phosphorylated by PKD1 and regulates lamelli-
podia formation and membrane ruffling [22]. In view of the ability
of Ena/VASP proteins to form functional tetramers [23], we can
hypohesize that the phosphorylation of the two members of Ena/
VASP family may implicate a similar function, and a similar
regulatory pathway. In line with our results on hMena11a
phosphorylation, Janssens K and coauthors [22] report that Evl-I
is strongly phosphorylated in the HER2 overexpressing SKBr3
breast cancer cell line, whereas a lower level of P-Evl-I expression is
shown in MCF7 and T47D cells.
Growth factor treatment further increased the hMena11a
phosphorylation in HER2 overexpressing cancer cells, suggesting
that stroma mediated paracrine mechanisms not only induce
hMena overexpression, but also sustain the phosphorylation of
hMena11a. Members of HER family take part in a complex array
of combinatorial interactions through the formation of homo and
heterodimers between the different family members and not only
the preferred heterodimerization partner HER2, but also EGFR
and recently HER3 have been defined as important therapeutic
targets in breast cancer [6]. Our data demonstrating that hMena/
hMena11a expression as well as hMena11a phosphorylation are
induced by EGF and NRG1, indicate that hMena/hMena11a are
downstream to different receptor complexes (EGFR/HER2 and
HER2/HER3), and might thus represent a relevant target for
therapeutic regulation.
Functionally, we suggest a dynamic reciprocal cross-talk
between ErbB family signalling and actin cytoskeleton regulators,
as pointed out by the results that hMena/hMena11a knock-down
reduces the phosphorylation of HER3, MAPK and AKT and
abolishes the EGF and NRG1 mediated phosphorylation of HER2
and EGFR. The HER2/HER3 receptor pair form the most
potent mitogenic receptor complex and HER2 overexpressing
tumors frequently show phosphorylated HER3 [24]. Consistently,
in our model the HER2 overexpressing MCF7 cells showed a
ligand independent phosphorylated status of HER3 receptor. One
could envisage that hMena/hMena11a are involved in the
heterodimerization of HER2/HER3 as suggested by the reduction
of HER3 phosphorylation observed in hMena/hMena11a knock
down cells. This could also be the reason for the reduction of
phosphorylated AKT and MAPK in untreated cells, since the
HER2/HER3 complex is a potent activator of PI3K and MAPK
signalling [25]. As already reported, growth factor stimulation
determines a down-regulation of HER3 caused by the ligand-
stimulated degradation of the receptor, that does not involve
HER2 despite the dimerization of the two receptors [26]. This
reduction at the protein level is more evident in hMena/hMena11a
silenced cells, suggesting a role of hMena/hMena11a also in the
post-transcriptional mechanisms regulating the HER3 receptor.
The hypothesis that hMena/hMena11a play a role in the
Figure 6. hMena overexpression adds prognostic information in HER2 overexpressing tumors. Kaplan-Meier estimates of disease-free
survival (DFS) for hMena and HER2 status show that hMena/HER2 covariates have a different effect on DFS in relationship to the different phenotype
combinations. In particular, the lower percentage of disease free patients at 6 year follow up was found in the group of HER2+/hMena+ tumors
(p,0.0001).
doi:10.1371/journal.pone.0015852.g006
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heterodimerization and activation of the ErbB family of receptors,
an event sustained by actin cytoskeleton organization [27], is
reinforced by the reduction of ligand-dependent phosphorylation
of HER2 and EGFR in the hMena/hMena11a knock down cells.
hMena/hMena11a knock-down is accompanied by the inhibi-
tion of cell proliferation in HER2 overexpressing cells, inhibition
which become significant in EGF and NRG1 treated cells, thus
supporting the hypothesis that hMena/hMena11a are relevant
mediators of the EGF and NRG1 mitogenic signals. Data
presented here indicate the ability of hMena/hMena11a to sustain
EGF and NRG1-mediated signalling responsible for a proliferative
signature of breast cancer. The ErbB family is at the center of
converging signals for cell proliferation and motility and it could
be hypothesized that the regulation of hMena alternative splicing
could contribute to this different cell behaviour. In line with this
hypothesis, the recently described murine invasion isoform, Mena
INV, sensitizes rat mammary tumor cells to EGF-dependent
invasion and protrusion [28]. Moreover, in invasive tumor cells
the 11a isoform is down-modulated with respect to the stationary
ones [29], according with our previous data on the exclusive
expression of hMena11a isoform in epithelial non invasive breast
and pancreatic tumor cell lines [16,17] and with the recent finding
reporting the hMena11a expression under the control of epithelial
specific splicing regulators [18]. This suggests that the availability
of specific hMena isoform antibodies may represent a new tool in
the clinical management of breast cancer.
The clinical data presented herein indicate that hMena
cooperates with HER2 overexpression in breast cancer progres-
sion. In fact, HER2 overexpressing tumors lacking hMena
overexpression frequently showed inactivated PI3K and MAPK
pathways and the patients have a better prognosis with respect to
those co-overexpressing HER2 and hMena. Overexpression of
HER2 in the primary tumor represents one of the best prognostic
indicators of breast cancer progression [30]. HER2 positive
tumors were found to have elevated levels of phosphorylated
HER3 [24], suggesting that the recruitment of HER3 contributes
to malignant growth. On the other hand, co-overexpression of
multiple ErbB family members is associated with decreased
survival [31]. Although future studies are needed to clarify the
role of hMena and its isoforms in breast cancer progression, our
observation raised the possibility that hMena overexpression may
contribute in mediating the activation of various ErbB receptors.
As the inactivation of ErbB receptors is a new tool in cancer
treatment, future studies could lead to the development of hMena
overexpression as a marker of breast cancer progression.
Materials and Methods
Cell lines
The human breast carcinoma cell lines MCF7, BT474, SKBr3,
MDA-MB-361, T47D and BT549 purchased from the ATCC
(Rockville MD) were cultured in RPMI 1640 (Gibco, Invitrogen,
Pisley, UK) supplemented with 10% fetal calf serum, glutamine, at
37uC in 5% CO2-95% air. The DAL cell line was obtained from
the ascitic fluid of a breast cancer patient [32]. MCF7-HER2 and
MCF7-pcDNA3 stable transfectants were obtained by selecting
MCF7 cells transfected with HER2-pcDNA3.1 (kindly provided
by Dr. Oreste Segatto), and with the empty vector respectively,
using G418 500 mg/ml (Invitrogen) in complete culture medium.
BT549 and DAL stable transfectants (shown in Figure S2) were
obtained by selecting transfected hMena11a-pcDNA3.1 cells with
G418. All cell lines were routinely morphologically checked by
microscope, growth curve analysis by 3H-Thymidine incorpora-
tion assay and Mycoplasma detection (Roche, Monza, Italy).
Cell treatments
Cells were grown in 6 well plates to 50% confluence in RPMI
supplemented with 10% fetal bovine serum. Eighteen hours after
medium replacement with fresh medium containing 0.5% serum,
cells were treated with recombinant human EGF 100 ng/ml
(Promega Corporation, Madison, WI, USA), or NRG1 10 ng/ml
(Promega Corporation) for 24 h.
Herceptin (Roche, Monza, Italy) for clinical and in vitro use was
stored at 4uC and adjusted to the final concentration of 25 mg/ml
with culture medium containing 10% serum. Exponentially
growing cells were exposed to the treatment for 48 h. Treated
and control cells were washed and processed according to the
experiment to be done.
Western blot analysis
Cells were lysed for 30 min at 4uC in 10% glycerol, 0.1% SDS,
0.5% DOC, 1% NP-40 in PBS containing protease and
phosphatase-inhibitors. Lysates were centrifuged and protein
quantification of supernatants was determined using BCA Protein
Assay Reagent (Pierce, Rockford, IL, USA). Lysates (50 mg) were
resolved on 10% polyacrylamide gel and transferred to nitrocel-
lulose membrane (GE-Healthcare, Little Chalfont, UK). For
HER3 and Phospho-HER3 detection, 80 mg of lysates were used.
Blots were blocked for 1 h with 3% skimmed milk in TBST and
probed in 3% skimmed milk/TBST overnight at 4uC with the
following antibodies: 10 mg/ml anti-hMena rabbit CKLK1 (pan-
hMena) antibody [15]; 1 mg/ml anti-hMena11a rabbit antibody,
that we developed against a portion of the peptide 11a
(RDSPRKNQIVFDNRSYDS) by the use of the Primm service
(Primm srl, Milan, Italy), showing a similar pattern of reactivity
with the previously reported anti-Mena11a antibody [17] (charac-
terization of the antibody is reported in the Figure S2); anti-
Phospho-p44/42 MAPK (Thr202/Tyr204) mouse mAb, p44/42
MAPK rabbit antibody, Phospho-AKT (Ser473) antibody, AKT
antibody and Phospho-HER3 were all from Cell Signaling
Technology (Beverly, MA); anti-phospho-HER2 (Y1248) from
Upstate Biotechnology (Lake Placid, NY); anti-Neu C18, anti-
EGFR 1005 and anti-HER3 C17 were from Santa Cruz
Biotechnology (Santa Cruz, CA); anti-EGFR (pY1068) phosphos-
pecific antibody obtained from Biosource (Camarillo, CA). After 3
washes of 15 min each, blots were incubated with the appropriate
secondary antibody conjugated with HRP for 1 h and then
washed again three times. The protein signals were detected by
ECL kit (GE-Healthcare). For actin signal, blots were reprobed
with 1 mg/ml monoclonal anti-actin, mouse-ascites fluid clone
AC-40 (Sigma Aldrich, Poole, UK). X-ray films were scanned by
HP Scanjet 5470 and processed by Corel Photo Paint 12.
RNA extraction and real-time PCR
Five micrograms of total mRNA were extracted using Trizol
reagent (Life Technologies Inc, Rockville, MD, USA) to obtain the
relative cDNA by first strand cDNA synthesis kit (GE-Healthcare)
according to the manufacturer’s protocol. Real-time PCRs (RT-
PCR) were run on an ABI Prism 7900 RT-PCR machine (Applied
Biosystems) using the following cycling conditions: 50uC for 2 min,
95uC for 10 min, and 40 cycles at 95uC for 15 s each followed by
termination at 60uC for 1 min. Each sample contained 10 ng
template cDNA, 10 ml 2x Taqman Universal Master Mix (Applied
Biosystems), 100 nmol/L of each primer, and 200 nmol/L probe
in 20 ml volume. Amplification primers and probe (Assay ID
Hs00430216) of Taqman gene expression assay (Applied Biosys-
tem) were used for hMena. The b-Actin gene used as an
endogenous control was amplified using the Taqman gene
expression assay (Applied Biosystems). Data from triplicate
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samples were analyzed with SDS 2.1 software (Applied Biosystems)
and relative hMena mRNA expression levels were calculated using
the DDCT method.
Two-Dimensional Electrophoresis (2DE)
Cells were washed extensively with PBS, pellets lyophilized and
solubilized with 2DE solubilization buffer (9 M Urea, 10 mM
Tris, 4% CHAPS, 65 mM DTT, 2% IPG buffer ampholine pH 3-
10, protease inhibitor cocktail). Protein samples (250 mg) were
applied to 7 cm IPGstrips pH 3-10NL (GE-Healthcare) by in-gel
rehydration. Iso-electro Focusing (IEF) was performed with an
IPGphor system (GE-Healthcare) following a standard protocol as
described [33]. Strips were equilibrated in 50 mM pH 8.8 Tris-
HCl buffer containing 6 M urea, 30% glycerol, 2% SDS and 2%
DTT, followed by an incubation in the same buffer replacing
DTT with 2.5% iodoacetamide. The strips were loaded on the top
of 10% acrylamide SDS-PAGE gels for the second dimension
separation. Proteins were electrontransferred onto nitrocellulose
membranes and Western blot performed as described above.
Images were acquired at high resolution and 2D immunoreactivity
patterns analyzed using Progenesis PG240 v2005 software
(Nonlinear dynamics, Newcastle, UK). Relative molecular mass
(Mr) were estimated by comparison with Mr reference markers
(Precision, Bio-Rad, Hercules, CA, USA) and isoelectric point (pI)
values assigned to detected spots by calibration as described in the
GE-Healthcare guidelines.
Phosphatase treatment
Lambda Protein Phosphatase (l-PPase) (NewEngland BioLabs,
Ipswich, MA, USA) treatment was performed as described [34]
with modifications. In brief, pelleted cells (256106) were
lyophilized and resuspended in lysis buffer (1% w/v NP-40, 1%
w/v SDS, 50 mM Tris pH 7.6, 150 mM NaCl, protease inhibitor
cocktail). Sixty ml of lysate, corresponding to 600 mg of protein,
were brought to a final volume of 600 ml with deionized water
followed by the addition of 20 ml of 20 mM MnCl2 solution and
20 ml of l-PPase buffer. For each addition, the solution was gently
mixed. The mixture was divided into two aliquots, and 300 units
of l-PPase was added to one of the aliquots. After mixing, aliquots
were incubated for 6 h at 30uC. Proteins were acetone precipitated
at 220uC and used for 2DE analysis.
Small-interfering RNA treatment
Cells in exponential growth phase were plated in 6-well plates
36105 cells/well. After 24 h cells were transfected with 100 nmol/
L hMena-specific pooled siRNA duplexes (siENA SMART pool)
or control non-specific siRNA (Dharmacon, Lafayette, CO) using
Lipofectamine 2000 reagent (Invitrogen). After 72 h cells were
analyzed by Western blot or, after 24 h, cells were serum starved
for 18 h and then treated with 100 ng/ml EGF or 10 ng/ml
NRG1 for additional 24 h for Western blot analysis or
[3H]thymidine incorporation assay.
[3H]Thymidine Incorporation Assay
The day after siRNA transfection cells from each well were
transferred to 4 wells of 48-well-plates and treated with growth
factors as above described. For 3H-thymidine incorporation
assay, 3H-thymidine (Perkin Elmer Life and Analytical Sciences,
Boston, MA) was added at 5 mCi/mL for 4 h on the last day of
treatment. Following medium removal, cells were washed twice
with cold PBS, treated with 10% trichloroacetic acid for 30 min
at 37uC, solubilized with 0.4 N NaOH and counted for
incorporation of 3H on b liquid scintillation counter in 5 mL of
scintillation fluid. Each experiment was done in quadruplicate
and results were expressed as the means of at least three separate
experiments.
Patients and Tissue Specimens
hMena was analyzed by immunohistochemistry in a series of
286 breast cancer patients ranging in age 28–86 years (median, 53
years) subjected to breast cancer surgery at the Regina Elena
Cancer Institute (Rome, Italy) between 2000 and 2004. Follow-up
data were obtained from hospital charts and by correspondence
with the referring physicians. As shown in Table 1, the group
included 246 (86%) invasive ductal carcinomas, 28 (10%) invasive
lobular carcinomas, and 12 (4%) other histotypes. Among these,
171 (60%) were pT1, 80 (29%) pT2 and 28 (11%) pT3/4, 154
(54%) were node negative and 132 (46%) node positive, 27 (10%)
G1, 146 (54%) G2 and 96 (34%) G3. Ki67 was found positive in
122 tumors (43%) and negative in 164 (57%), while hMena was
overexpressed in 190 (66%) cases and negative in 96 (34%).
Tumors were graded according to Bloom and Richardson and
staged according to the Unione Internationale Contre le Cancer
tumor-node-metastasis system criteria and histologically classified
according to the World Health Organization [35]. Moreover, we
studied hMena distribution according to the molecular subtypes
identified by a few protein biomarkers, namely ERa, PgR, HER2.
They were 177 (62%) Luminal A (LA, ERa/PgR positive and
HER2 negative), 34 (12%) Luminal B (LB ERa/PgR positive and
HER2 positive), 27 (9%) Triple Negatives (TN, ERa/PgR,HER2
negative) and 48 (17%) HER2 subtypes (HS, ERa/PgR negative,
HER2 positive).
The study was reviewed and approved by the ethics committee
of the Regina Elena National Cancer Institute, and written
informed consent was obtained from all patients.
Immunohistochemistry and CISH
hMena immunostaining was performed by using a monoclonal
antibody from BD Transduction (San Jose, CA, USA; 2.5 mg/ml).
Anti estrogen (6F11 MoAb) and progesterone (1A6 MoAb)
receptors were purchased from Novocastra (Menarini, Florence,
Italy); HER-2 (A0485 pAb) and Ki67 (MIB-1 MoAb) antibodies
from DAKO (Milan, Italy); phospho-p44/42 MAPK and
phospho-AKT antibodies from Cell Signaling (SIAL, Rome,
Italy). Immunostaining was revealed by a streptavidin-biotin
enhanced immunoperoxidase technique (Super Sensitive Multi-
Link, Menarini) in an automated autostainer. Diaminobenzidine
was used as chromogenic substrate.
The intensity of hMena cytoplasmic staining was scored from 0
to 3 as previously described [15]; Ki67 percentage, based on the
median value of our series, was regarded as high if .15% of the
cell nuclei were immunostained.
HER-2 immunostaining was performed following the manifac-
turer’s protocol and protein overexpression was determined as
defined in the HercepTest kit guide: score 0, 1+, 2+, 3+. All IHC
2+ tumors were analyzed with chromogenic in situ hybridization
(CISH) as previously described [36] in order to determine the
HER2 gene copy level. For statistical analysis, negative (HER2
IHC score 0, 1+ and 2+ cases lacking gene amplification) and
positive (HER2 IHC score 2+ with gene amplification cases and
score 3+) groups were created.
P-MAPK was considered positive when .25% of the neoplastic
cells showed a distinct cytoplasmic staining. Breast cancers
showing a distinct and intense cytoplasmic immunostaining for
P-AKT were scored as strongly positive (2+), independent of the
percentage of stained cells.
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Evaluation of the immunohistochemical results was done
independently and in blinded manner by two investigators (M.M.,
E.M.).
Statistical analysis
All experiments were repeated a minimum of three times. Data
collected from [3H]thymidine incorporation assay were expressed
as means 6 standard deviation (SD). The data presented in some
figures are from a representative experiment, which was
qualitatively similar in the replicate experiments. Statistical
significance was determined by Student’s t test (two tailed)
comparison between two groups of data sets. Asterisks indicate
significant differences of experimental groups compared with the
corresponding control condition (P,0.05, see figure legends). All
the analysis were performed using GraphPad Prism 4, V4.03
software (GraphPad Inc., San Diego, CA). Change in the
phosphorylation status was evaluated using Progenesis PG240
v.2006 software (Nonlinear dynamics) by optical density indicated
as normalized spot volume. Normalization was done multiplying
the total spot volume by the constant factor 100 which produces
spot percentage volume.
The Chi-Square test and Fisher exact text, when appropriate
were used to assess the relationship between hMena positivity and
the other biological parameters (HER2, Ki-67, P-AKT, P-
MAPK). The Chi-Square test for linear trend was also applied.
The disease-free survival (DFS) curves were estimated by the
Kaplan-Meier product-limit method. The log-rank test was used
to assess differences between subgroups. Significance was defined
at the p,0.05 level. Statistical analysis for survival were performed
with SPSS statistical software version 11.5 (SPSS inc., Chicago IL,
USA).
Supporting Information
Figure S1 Western Blot analysis of MCF7 and MDA-MB-361
after 72 h transfection with control and hMena/hMena11a -
specific siRNAs with pan-hMena antibody. As loading control
blots were probed with anti-Actin antibody (1 mg/ml).
(TIF)
Figure S2 Characterization of anti-hMena11a antibo-
dy. A. Western blot analysis with 1 mg/ml of anti-hMena11a
antibody on lysates of SKBr3, expressing hMena11a, and BT549,
negative for hMena11a expression, transfected with either control
vector (pcDNA3) or hMena11a. B–C. Western blot analysis of
DAL cells transfected with either control vector (pcDNA3) or
hMena11a with 1 mg/ml (B) or 0.1 mg/ml (C) of anti-hMena11a
antibody. As loading control blots were probed with anti-Actin
antibody (1 mg/ml).
(TIF)
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